Parion Sciences, Inc.

William Robert Thelin

Michael Ross Johnson

Richard C Boucher

Tomas Navratil

Brian Button

Ronald A Aungst, Jr

James B Fink

Anthony James Hickey

Mark Jeffrey Edhouse

Philip Jerome Driver

Stuart Robert Abercrombie

Paul Boucher

Nicholas O Heijne

Donal Joseph Taylor

Jonathan Hugh Wilkins

Brian M Button

Provided are mucolytic agents represented by formula (Ia)-(Id): where the structural variables R, R, Rand Rare as defined herein. Also provided are a variety of methods of treatment which take advantage of the mucolytic properties of the compounds represented by formula (Ia)-(Id).

Monothiol mucolytic agents

Sodium channel blockers represented by the formula: are provided where the structural variables are defined herein. The invention also includes a variety of compositions, combinations and methods of treatment using these inventive sodium channel blockers.

Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases

Provided are mucolytic compounds that are more effective, and/or absorbed less rapidly from mucosal surfaces, and/or are better tolerated as compared to N-acetylcysteine (NAC) and DTT. The compounds are represented by compounds of Formula I which embrace structures (Ia)-(Ib): where the structural variables are as defined herein.

Prodrugs of dithiol mucolytic agents

Embodiments disclosed herein are directed to methods, compositions and apparatus for administering active agents to the lungs of a subject.

Methods of treatment

Provided are dithiol mucolytic agents. These agents increase the liquefaction of mucus in a patient with excessive mucus or mucus with increased viscoelastic, cohesive, or adhesive properties. Also provided are a variety of methods of treatment using these inventive mucolytic agents.

Dithiol mucolytic agents

Provided are methods of treating a variety of disorders of the skin with inhibitors of the epithelial sodium channel (ENaC). The inhibitors are represented by formula (I)-(IV): where R is defined herein.

Sodium channel blockers for skin disorders

An aerosol preparation assembly includes an entrainment chamber defining an entrainment volume. The entrainment chamber includes a gas inlet port, an aerosol inlet port and an outlet port. The entrainment chamber is configured such that a velocity of a flow of a gas within the entrainment volume is less than a velocity of the flow of the gas within the gas inlet port. The entrainment chamber is configured such that at least a portion of inlet aerosol is entrained into the flow of the gas within the entrainment volume to produce an entrained aerosol flow at the outlet port. The particle selection chamber is configured to receive the entrained aerosol flow and produce an outlet aerosol flow. The particle selection chamber and nozzle are collectively configured such that a volumetric median diameter of the outlet aerosol flow is less than a volumetric median diameter of the inlet aerosol.

Aerosol delivery systems, compositions and methods

The present invention concerns methods, compositions and apparatus for administering active agents to the lungs of a subject.

Growing community of inventors

Chapel Hill, NC, United States of America

William Robert Thelin